Editas Medicine
EDIT
313 hedge funds and large institutions have $2.96B invested in Editas Medicine in 2021 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 110 increasing their positions, 85 reducing their positions, and 43 closing their positions.
78% more call options, than puts
Call options by funds: $199M | Put options by funds: $112M
33% more capital invested
Capital invested by funds: $2.23B → $2.96B (+$726M)
29% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 85
2% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 43
0% more funds holding
Funds holding: 312 → 313 (+1)
2.09% less ownership
Funds ownership: 78.99% → 76.9% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$24.1M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$22.6M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$13.3M |
| 4 |
DVF
Discovery Value Fund
Singapore
|
+$13M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$58.1M |
| 2 |
Two Sigma Investments
New York
|
-$20.9M |
| 3 |
D.E. Shaw & Co
New York
|
-$17.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.1M |
| 5 |
Renaissance Technologies
New York
|
-$11.7M |
EDIT Hedge Fund Activity: Q2 2021 in Review
313 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2021, worth a combined $2.96B — up 33% from $2.23B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new EDIT positions and 43 closed out — a net gain of 1 holder — while 110 added to existing stakes and 85 trimmed.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $24.1M. The largest seller was ARK Investment Management, cutting an estimated $58.1M.
- 313 institutional investors held Editas Medicine (EDIT) as of Q2 2021, up from 312 in Q1 2021.
- Funds reported $2.96B of Editas Medicine stock for Q2 2021, up 33% quarter-over-quarter.
- 44 funds opened new Editas Medicine positions in Q2 2021 and 43 closed out, a net change of +1 holder.
- The largest Editas Medicine buyer in Q2 2021 was Sumitomo Mitsui Trust Group, an estimated $24.1M added.
- The largest Editas Medicine seller in Q2 2021 was ARK Investment Management, an estimated $58.1M sold.
Based on aggregated 13F filings for Q2 2021.